CXCR-2 mutant as well as preparation method and application thereof
CXCL2-CXCR-2 signaling pathway is blocked through CXCR-2 mutant protein, which prompts the conversion of microglia into M2 type, solving the problem of cerebral hematoma removal after cerebral hemorrhage, significantly improving the prognosis of cerebral hemorrhage and reducing nerve damage.
Patent Information
- Application Number
- CN202411075443.7
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-06
- Publication Date
- 2024-11-22
- Estimated Expiration
- 2044-08-06
AI Technical Summary
The removal of cerebral hematoma after cerebral hematoma is difficult to effectively promote. Existing drugs have the risk of thromboembolic and the treatment effect is uncertain. Microglia can easily lead to the expression of inflammatory factors during the hematoma removal process and damage neurons.
A CXCR-2 mutant protein was designed, prepared by recombinant plasmid and protein expression methods, blocking the CXCL2-CXCR-2 signaling pathway, prompting the conversion of microglia to M2 type, and thus promoting the absorption of cerebral hematoma.
In the collagenase-induced cerebral hemorrhage model, the CXCR-2 mutant protein significantly improved the absorption effect of cerebral hematoma, improved the neurofunction score in rats, and reduced the prognostic risk of cerebral hemorrhage.
Smart Images

Figure CN118994362A_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the field of molecular biology, and specifically relates to a CXCR-2 mutant and a preparation method and application thereof. Background Art
[0002] In the acute stage of cerebral hemorrhage, due to the relatively small volume of hematoma, the risk factor of surgical removal of hematoma may be higher than the treatment effect, and the surgical operation will inevitably affect the normal brain tissue and nerves, leading to irreversible side effects. The main means of medical intervention for cerebral hematoma is the use of antihypertensive drugs and hemostatic drugs, but they are aimed at controlling the expansion of hematoma rather than promoting hematoma absorption. The use of hemostatic drugs also has the risk of thromboembolic events, and the long-term benefits are uncertain. In recent years, with the development of precise stereotactic technology for the brain, minimally invasive surgery combined with in situ drug administration has effectively improved the treatment effect of cerebral hemorrhage. Studies have shown that minimally invasive surgery and thrombolytic drug treatment within 72 hours after cerebral hemorrhage have a trend of improving neurological function for 180 days. Therefore, the development of drugs that can promote the removal of cerebral hematoma and the use of in situ treatment through the surgical channel established by minimally invasive surgery can provide a new idea for the treatment of cerebral hemorrhage and is expected to improve the treatment effect of cerebral hemorrhage.
[0003] Existing studies have shown that the self-clearance of cerebral hematoma mainly occurs through three pathways: the microglia / macrophage system is the first line of defense for cerebral hemorrhage and the main phagocytic system that mediates hematoma clearance; some scavenger receptors (such as CD36, CD47, SRA, etc.) participate in endocytosis, which is of great significance for maintaining brain balance and phagocytosis, and can further promote the clearance of cerebral hematoma; in addition, some upstream regulatory systems (such as Nrf2 and PPAR-γ) can also indirectly promote the clearance of cerebral hematoma. Among them, more and more evidence shows that microglia play a key role in the clearance of hematoma. When cerebral hematoma is formed, microglia are rapidly activated and can be polarized into two phenotypes, M1 and M2. The M1 type expresses a series of inflammatory factors, which leads to neuronal apoptosis, nerve conduction bundle rupture, and blood-brain barrier damage. In contrast, the M2 type mainly expresses anti-inflammatory factors, which can promote the phagocytosis of dead cells and blood fragments, thereby promoting the clearance of cerebral hematoma. Therefore, developing drugs that can regulate the polarization of microglia to M2 type, the first line of defense for cerebral hematoma, will help promote the clearance of cerebral hematoma and is also the focus of current neurological research on secondary brain injury after cerebral hemorrhage. Summary of the invention
[0004] The present invention discloses a CXCR-2 mutant and a preparation method thereof, wherein the mutant can improve the binding with the ligand chemokine 2 and promote the absorption of cerebral hematoma. The second purpose of the present invention is to provide the application of the CXCR-2 mutant.
[0005] In order to achieve the above first purpose, the technical solution of the present invention is: a CXCR-2 mutant, characterized in that: the amino acid sequence is MGEIRVDNFS LEDFFSGDID SYNYSSDPPF TLSDAAPCPS ANLDINRYAT TTTYTQTTQQSQTGQSQTMQ TTQYNRSTCS VTDTYQQQQA TADQYYAQTQ PTWAASKVNG WIFGSFLCKT YSYQQETTYYSSTQQQACTS MDRYLAIVHA TSTLIQKRHL VKYTCTTMWY QSQTQSQPTY TQRTTVKANP STVVCYENIGNNTSKWRTTQ RTQPQTYGYQ QPQQTMQYCY GFTLRTLFKA HMGQKHRAMR TTYATTQTYQ QCWQPYQTTQYTDTLMRTKL IKETCERQNE INKALEATET QGYQHSCQQP TTYAFIGQKF RHGLLKIMAN YGLVSKEFLAKEGRPSFVGSSSANTSTTLHHHHHHHHHH.
[0006] The method for producing CXCR-2 mutant protein is characterized by comprising the following steps:
[0007] (1) Preparation of recombinant plasmid;
[0008] (2) Vector transformation: Take out BL21(DE3) competent cells from -80°C and thaw on ice; add plasmid DNA to BL21(DE3) strain, mix gently, and incubate on ice; heat at 42°C by heat shock, place on ice, and then add room temperature LB culture medium, shake and incubate at 200 rpm, 37°C; spread the bacterial solution on LB agar plate containing ampicillin and incubate at 37°C overnight;
[0009] (3) Protein expression: Select a single colony on the agar plate and inoculate it into LB medium containing ampicillin, shake and culture it at 200 rpm, 37°C overnight; inoculate the bacterial solution into LB medium for expansion culture, shake and culture it at 200 rpm, 37°C until the OD600 of the bacterial solution reaches 0.6-0.8; add IPTG with a final concentration of 0.5 mM and shake and induce at 37°C;
[0010] (4) Lysis and washing:
[0011] Collect the bacterial solution after IPTG induction, centrifuge at 8000rpm, 4℃, collect the precipitate; add B-PER solution, ultrasonically break it in an ice bath, mix and repeat the lysis once; centrifuge at 11500rpm, 4℃, discard the supernatant; add Buffer 1 to wash the precipitate, ultrasonicate, centrifuge at 11500rpm, 4℃, 25min, discard the supernatant; add Buffer 2 to ultrasonicate; centrifuge at 11500rpm, 4℃, discard the supernatant; add ml Buffer 1 to ultrasonicate; centrifuge at 11500rpm, 4℃, 25min, discard the supernatant;
[0012] (5) Protein purification:
[0013] Add DeB to dissolve the precipitate, and suspend it overnight by magnetic stirring or in a chromatography cabinet; centrifuge at 11500rpm and 4°C, and collect the supernatant; purify by Ni column chromatography, collect the purified sample, and dialyze with a dialysis bag or ultrafiltration tube to remove DeB to obtain the purified protein.
[0014] A CXCR-2 mutant as a drug for clearing brain damage.
[0015] The brain injury includes a cerebral hematoma.
[0016] Beneficial effects:
[0017] Chemokine receptor-2 (CXCR-2) is expressed in microglial cells of some central nervous system diseases. After CXCR-2 binds to the ligand chemokine 2 (CXCL2), it can promote the transformation of microglial cells to M1 type. Blocking the CXCL2-CXCR-2 signaling pathway can reverse this transformation and promote the transformation of M1 to M2 type. The present invention is designed based on the sequence of CXCR-2 to obtain a new protein sequence, which can be recombinantly expressed to obtain a recombinant protein with good water solubility. In the collagenase-induced cerebral hemorrhage rat model, the recombinant protein can promote the absorption of rat cerebral hematoma. It can effectively improve the prognosis of cerebral hemorrhage. BRIEF DESCRIPTION OF THE DRAWINGS
[0018] Figure 1 This is a diagram of plasmid sequencing results.
[0019] Figure 2 This is the SDS-PAGE analysis of the recombinant protein.
[0020] Figure 3 This is a Western Blot analysis of the purified recombinant protein.
[0021] Figure 4 This is the sagittal view of the brain of rats in the blank control group.
[0022] Figure 5 Sagittal images of the brain of rats in the CXCR-2 intervention group.
[0023] Figure 6 This is the sagittal view of the brain of rats in the recombinant protein intervention group.
[0024] Figure 7 Sagittal view of normal rat brain. DETAILED DESCRIPTION
[0025] The present invention is further described below in conjunction with the accompanying drawings and embodiments.
[0026] Example 1
[0027] CXCR-2 mutant, the amino acid sequence is MGEIRVDNFS LEDFFSGDID SYNYSSDPPF TLSDAAPCPSANLDINRYAT TTTYTQTTQQ SQTGQSQTMQTTQYNRSTCS VTDTYQQQQA TADQYYAQTQ PTWAASKVNGWIFFGSFLCKTYSYQQETTYY SSTQQQACTS MDRYLAIVHA TSTLIQKRHL VKYTCTTMWYQSQTQSQPTYTQRTTVKANP STVVCYENIG NNTSKWRTTQ RTQPQTYGYQQPQQTMQYCY GFTLRTLFKA HMGQKHRAMRTTYATTQTYQ QCWQPYQTTQYTDTLMRTKL IKETCERQNE INKALEATET QGYQHSCQQPTTYAFIGQKFRHGLLKIMAN YGLVSKEFLA KEGRPSFVGS SSANTSTTL HHHHHHHHHH
[0028] Prepared as follows:
[0029] 1. The recombinant plasmid was commissioned to be synthesized by GenScript, using pET-22b as the vector. Figure 1 The results of plasmid sequencing.
[0030] 2. Plasmid transformation: Take out BL21(DE3) competent cells from -80℃ and thaw on ice; add 100ng of plasmid DNA to BL21(DE3) strain, mix gently, and incubate on ice for 30 minutes; heat at 42℃ for 90 seconds, then ice bath for 3min; add 100μl of room temperature LB culture medium, shake and incubate at 200rpm, 37℃ for 60min; spread the bacterial liquid on LB agar plate containing ampicillin (100μg / ml) and incubate at 37℃ overnight.
[0031] 3. Protein expression: Select a single colony on the agar plate and inoculate it into 20 ml LB medium containing ampicillin (final concentration of 50 μg / L), shake and culture overnight at 200 rpm, 37°C; inoculate the bacterial solution into 1 L LB medium for expansion culture, shake and culture at 200 rpm, 37°C until the OD600 of the bacterial solution reaches 0.6-0.8; add IPTG with a final concentration of 0.5 mM and shake and induce at 37°C for 4 h.
[0032] 4. Lysis and washing: collect the bacterial solution after IPTG induction, centrifuge at 8000rpm, 4℃ for 5min, collect the precipitate; add B-PER solution, ultrasonically disrupt (ice bath) for 25min, 2s on and 8s off, 30% power, mix and repeat the lysis once; centrifuge at 11500rpm, 4℃, 25min, discard the supernatant; add 17ml Buffer1 to wash the precipitate, ultrasonically for 15min (ice bath), 2s on and 8s off, 30% power; centrifuge at 11500rpm, 4℃, 25min, discard the supernatant; add 17ml Buffer2 and ultrasonically for 15min (ice bath); centrifuge at 11500rpm, 4℃, 25min, discard the supernatant; add 17ml Buffer1 and ultrasonically for 15min (ice bath); centrifuge at 11500rpm, 4℃, 25min, discard the supernatant.
[0033] 5. Protein purification: Add 10 ml of DeB to the precipitate after centrifugation to dissolve the precipitate, stir magnetically for 1.5 hours (room temperature) or suspend in a chromatography cabinet overnight (4°C); centrifuge at 11500 rpm, 4°C, 25 minutes, collect the supernatant; purify by Ni column chromatography, collect the purified sample, dialyze with a dialysis bag or ultrafiltration tube to remove DeB, and obtain the purified protein.
[0034] Figure 2 The SDS-PAGE of the recombinant protein, where M1 is the protein molecular weight standard, M2 is the WB marker, PC1 is fetal bovine serum albumin (1 μg), PC2 is fetal bovine serum albumin
[0035] (2 μg), NC is cell lysate without induction, 1 is cell lysate induced at 16 h and 15 °C, 2 is cell lysate induced at 4 h and 37 °C, NC1 is supernatant of cell lysate without induction, 3 is supernatant of cell lysate induced at 16 h and 15 °C, 4 is supernatant of cell lysate induced at 4 h and 37 °C, NC2 is precipitate of cell lysate without induction, 5 is precipitate of cell lysate induced at 16 h and 15 °C, and 6 is precipitate of cell lysate induced at 4 h and 37 °C. Figure 3 This is a Western Blot analysis of the purified recombinant protein.
[0036] Example 2
[0037] Animal experiments
[0038] In the collagenase-induced cerebral hemorrhage rat model, compared with the blank control group and the CXCR-2 intervention group, the recombinant protein can promote the clearance of cerebral hematoma in rats.
[0039] Experimental groups (6 rats in each group as parallel experiments): ① blank control group, ② CXCR-2 intervention group, ③ this recombinant protein intervention group
[0040] Experimental methods and results:
[0041] (1) Establishment of rat cerebral hemorrhage model
[0042] After the rats were weighed, they were anesthetized with 7% chloral hydrate intraperitoneally (5 ml / kg). Spontaneous breathing was ensured during the operation. The rats were fixed prone on a cranial stereotaxic instrument, the scalp was cut, the anterior fontanelle was taken as the origin, the needle was placed 0.2 mm forward, 2 mm laterally to the right, and the depth of 3.7 mm was used as the injection point. The skull was drilled with a skull drill. After the needle was inserted, 0.2 U type IV collagenase was slowly injected into the right striatum at 2 μL / min. After the injection was completed, the needle was retained for 10 minutes, and then the needle was slowly withdrawn at 1 mm / min. An injection tube was fixed at the injection position for drug administration.
[0043] (2) Drug treatment
[0044] Blank control group: 4 hours after the rats were injected with collagenase, 20 μl of PBS solution was slowly injected from the injection channel.
[0045] CXCR-2 intervention group: 4 hours after the rats were injected with collagenase, 20 μl of CXCR-2 suspension (concentration of about 0.70 mg / ml PBS solution) was slowly injected from the injection channel.
[0046] The recombinant protein intervention group: 4 hours after the rats were injected with collagenase, 20 μl of the recombinant protein solution in PBS (concentration of about 0.70 mg / ml PBS solution) was slowly injected from the injection channel.
[0047] Normal control group: Rats were not treated with collagenase, and 20 μl of PBS solution was slowly injected through the injection channel.
[0048] (3) Observation of cerebral hematoma
[0049] 24 hours after the administration, the rats were weighed and anesthetized, the chest and abdomen were opened in a supine position to fully expose the heart and liver, the injection needle was inserted into the left ventricle and the right atrial appendage was cut open. Physiological saline was quickly perfused until the liver turned white, and after the clear liquid flowed out of the right atrial appendage, 4% paraformaldehyde fixative was used, first quickly and then slowly perfused until the rat liver became hard and the limbs were stiff, the head was cut off and the brain was removed, the brain tissue was fixed in 4% paraformaldehyde, and the brain was cut open from the sagittal plane above the injection site to observe the hematoma. The severity of brain hematoma in rats in the recombinant protein intervention group was significantly lower than that in the blank control group and the CXCR-2 intervention group. Figure 4 This is the sagittal image of the brain of rats in the blank control group. Figure 5 This is the sagittal image of the brain of rats in the CXCR-2 intervention group. Figure 6 This is the sagittal image of the brain of rats in the recombinant protein intervention group. Figure 7 Sagittal view of normal rat brain.
[0050] Example 3
[0051] In the animal neurological function evaluation test, rats treated with recombinant protein scored higher, indicating that recombinant protein can effectively improve the prognosis of cerebral hemorrhage.
[0052] Experimental groups (6 rats in each group as parallel experiments): ① blank control group, ② CXCR-2 intervention group, ③ this recombinant protein intervention group
[0053] Experimental methods and results:
[0054] (1) The method for establishing rat cerebral hemorrhage model is the same as above
[0055] (2) The administration method of each test group is the same as above
[0056] (3) Animal neurological function evaluation
[0057] Neurological function of rats in each group was evaluated at 24h, 2, 4, and 7 days after administration. Evaluation items:
[0058] ① Spontaneous rotation: 0-3, 0 means no rotation, 3 means continuous rotation;
[0059] ② Hindlimb contraction: 0-3, 0 is immediate contraction, 3 is no retraction after hindlimb lateral displacement;
[0060] ③ Bilateral forepaw grasping: 0-3, with 0 being normal grasping and 3 being completely unable to grasp;
[0061] ④Beam walking ability: 0-3 levels, 0 being able to quickly pass the scale, and 3 being unable to stand on the scale for more than 10 seconds.
[0062] The results showed that the neurological function evaluation results of rats with cerebral hemorrhage treated with the recombinant protein were significantly better than those of the blank control group and the CXCR-2 intervention group during the recovery period.
[0063] Table 1 shows the results of neurological function evaluation
[0064]
Claims
1. A CXCR-2 mutant, characterized in that: The amino acid sequence is MGEIRVDNFS LEDFFSGDIDSYNYSSDPPF TLSDAAPCPSANLDINRYAT TTTYTQTTQQ SQTGQSQTMQ TTQYNRSTCSVTDTYQQQQATADQYYAQTQ PTWAASKVNG WIFGSFLCKTYSYQQETTYY SSTQQQACTS MDRYLAIVHA TSTLIQKRHLVKYTCTTMWY QSQTQSQPTY TQRTTVKANP STVVCYENIGNNTSKWRTTQ RTQPQTYGYQ QPQQTMQYCYGFTLRTLFKAHMGQKHRAMR TTYATTQTYQ QCWQPYQTTQ YTDTLMRTKLIKETCERQNE INKALEATETQGYQHSCQQP TTYAFIGQKFRHGLLKIMAN YGLVSKEFLA KEGRPSFVGS SSANTSTTLHHHHHHHHHH.
2. A method for preparing the CXCR-2 mutant protein according to claim 1, characterized in that: The following steps are involved: (1) Preparation of recombinant plasmid; (2) Vector transformation: Take out BL21(DE3) competent cells from -80°C and thaw on ice; add plasmid DNA to BL21(DE3) strain, mix gently, and incubate on ice; heat at 42°C by heat shock, place on ice, and then add room temperature LB culture medium, shake and incubate at 200 rpm, 37°C; spread the bacterial solution on LB agar plate containing ampicillin and incubate at 37°C overnight; (3) Protein expression: Select a single colony on the agar plate and inoculate it into LB medium containing ampicillin, shake and culture it at 200 rpm, 37°C overnight; inoculate the bacterial solution into LB medium for expansion culture, shake and culture it at 200 rpm, 37°C until the OD600 of the bacterial solution reaches 0.6-0.8; add IPTG with a final concentration of 0.5 mM and shake and induce at 37°C; (4) Lysis and washing: Collect the bacterial solution after IPTG induction, centrifuge at 8000rpm, 4℃, collect the precipitate; add B-PER solution, ultrasonically break it in an ice bath, mix and repeat the lysis once; centrifuge at 11500rpm, 4℃, discard the supernatant; add Buffer 1 to wash the precipitate, ultrasonicate, centrifuge at 11500rpm, 4℃, 25min, discard the supernatant; add Buffer 2 to ultrasonicate; centrifuge at 11500rpm, 4℃, discard the supernatant; add ml Buffer 1 to ultrasonicate; centrifuge at 11500rpm, 4℃, 25min, discard the supernatant; (5) Protein purification: Add DeB to dissolve the precipitate, and suspend it overnight by magnetic stirring or in a chromatography cabinet; centrifuge at 11500rpm and 4°C, and collect the supernatant; purify by Ni column chromatography, collect the purified sample, and dialyze with a dialysis bag or ultrafiltration tube to remove DeB to obtain the purified protein.
3. Use of a CXCR-2 mutant as a drug for clearing brain damage.
4. The use according to claim 3, characterized in that: The brain injury includes a cerebral hematoma.
Citation Information
Patent Citations
Thrombopoietic activity of tyrosyl-TRNA synthetase polypeptides
CN102105164A
CXCR2 binding polypeptides
CN103328512A
Biparatopic binding polypeptides for CXCR2 and uses thereof
CN104487456A
CCR-2 mutant and application thereof
CN114920821A
Pharmaceutical composition for alleviating or treating sequelae of cerebral infarction
WO2024048899A1
